Virological rebound and low drug levels of unknown origin under long-acting Cabotegravir (CAB)/Rilpivirine (RPV)

被引：0
|
作者：
Ruff, F. [1 ]
Kalubi, M. [1 ]
Hampel, B. [1 ,2 ]
机构：
[1] Checkpoint Zurich, Zurich, Switzerland
[2] Univ Zurich, Epidemiol Biostat & Prevent Inst, Dept Publ & Global Hlth, Zurich, Switzerland
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
EACS2023:
引用
收藏
页码：783 / 784
页数：2
相关论文
共 41 条
  • [1] Top practices for implementing cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) in European clinics
    Olalla, Julian
    Gutner, Cassidy
    Pascual-Bernaldez, Miguel
    Hernandez, Beatriz
    Dakhia, Samia
    Slama, Laurence
    Crusells Canales, Maria Jose
    Lutz, Thomas
    van der Valk, Mark
    van Welzen, Berend
    Florence, Eric
    Barnes, Nicola
    Cooper, Owen
    Filipenko, Dina
    Czarnogorski, Maggie
    [J]. HIV MEDICINE, 2022, 23 : 27 - 28
  • [2] Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine
    Ripamonti, Diego
    Borghetti, Alberto
    Zazzi, Maurizio
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (10) : 2720 - 2724
  • [3] Perceptions of cabotegravir and rilpivirine long-acting (CAB plus RPV LA) from patients in the CAB plus RPV implementation study in European locations (CARISEL)
    Lutz, Thomas
    Jeanmaire, Eliette
    Portilla, Joaquin
    Scherzer, Jenny
    Trehan, Rekha
    Pascaul-Bernaldez, Miguel
    DeMoor, Rebecca
    Ait-Khaled, Mounir
    Hadi, Monica
    Anand, Savita Bakhshi
    Low, Emma L.
    Czarnogorski, Maggie
    Gutner, Cassidy A.
    Neumann, Jeanette
    [J]. HIV MEDICINE, 2023, 24 : 20 - 21
  • [4] Perceptions of cabotegravir and rilpivirine long-acting (CAB plus RPV LA) from patients in the CAB plus RPV Implementation Study in European Locations (CARISEL)
    Lutz, T.
    Jeanmaire, E.
    Portilla, J.
    Scherzer, J.
    Trehan, R.
    Pascual-Bernaldez, M.
    DeMoor, R.
    Ait-Khaled, M.
    Hadi, M.
    Anand, S.
    Low, E.
    Czarnogorski, M.
    Gutner, C.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 117 - 118
  • [5] Real life Cabotegravir (CAB) and Rilpivirine (RPV) pharmacokinetics among PLHIV treated with CAB RPV Long Acting (LA IM)
    Seang, S.
    Abdi, B.
    Valantin, M-A
    Ktorza, N.
    Tubiana, R.
    Faycal, A.
    Schneider, L.
    Saliba, S.
    Pourcher, V.
    Peytavin, G.
    Katlama, C.
    [J]. HIV MEDICINE, 2023, 24 : 482 - 483
  • [6] Implementation of cabotegravir and rilpivirine long-acting (CAB plus RPV LA): primary results from the CAB plus RPV Implementation Study in European Locations (CARISEL)
    Van Welzen, B.
    Vandekerckhove, L.
    Jonsson-Oldenbuettel, C.
    Hocqueloux, L.
    Ait-Khaled, M.
    Bontempo, G.
    DeMoor, R.
    Scherzer, J.
    D'Amico, R.
    Barnes, N.
    Hadi, M.
    Low, E.
    Anand, S.
    Czarnogorski, M.
    Gutner, C.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 71 - 72
  • [7] Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine
    Mazzitelli, Maria
    Avolio, Antonio
    Carandina, Riccardo
    Parisi, Saverio
    Wensing, Annemarie
    Cattelan, Annamaria
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (08) : 2074 - 2076
  • [8] COST-EFFECTIVENESS OF CABOTEGRAVIR (CAB) plus RILPIVIRINE (RPV) LONG-ACTING (LA) IN PEOPLE LIVING WITH HIV (PLHIV) IN AUSTRIA
    Uhl, G.
    Schroeder, M.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S125 - S125
  • [9] Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
    Daryl Hodge
    David J. Back
    Sara Gibbons
    Saye H. Khoo
    Catia Marzolini
    [J]. Clinical Pharmacokinetics, 2021, 60 : 835 - 853
  • [10] Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
    Hodge, Daryl
    Back, David J.
    Gibbons, Sara
    Khoo, Saye H.
    Marzolini, Catia
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 835 - 853
12345